EPISODE · Jul 28, 2025 · 40 MIN
Joel Stanley: CEO of AJNA BioSciences
from Leap Together Podcast · host Leapcure Inc.
In this episode of Leap Together, host Zach Gobst sits down with Joel Stanley, founder and former CEO of Charlotte’s Web, and now CEO of AJNA Biosciences, to explore the pioneering path from supplement to FDA-approved botanical drug. Joel shares the powerful origin story of Charlotte’s Web, the lessons learned from navigating the unregulated CBD market, and how those insights now fuel his mission to bring safe, standardized plant-based therapeutics to patients through AJNA Biosciences.Learn how Joel and his team are working to bridge the gap between natural medicine and clinical science, what it takes to build physician advocacy, and why access, not just efficacy, is the next frontier in healthcare innovation.Whether you're a clinical leader, researcher, or founder, tune into this episode for a blueprint for building science-backed solutions that start with compassion.
What this episode covers
In this episode of Leap Together, host Zach Gobst sits down with Joel Stanley, founder and former CEO of Charlotte’s Web, and now CEO of AJNA Biosciences, to explore the pioneering path from supplement to FDA-approved botanical drug. Joel shares the powerful origin story of Charlotte’s Web, the lessons learned from navigating the unregulated CBD market, and how those insights now fuel his mission to bring safe, standardized plant-based therapeutics to patients through AJNA Biosciences.Learn how Joel and his team are working to bridge the gap between natural medicine and clinical science, what it takes to build physician advocacy, and why access, not just efficacy, is the next frontier in healthcare innovation.Whether you're a clinical leader, researcher, or founder, tune into this episode for a blueprint for building science-backed solutions that start with compassion.
NOW PLAYING
Joel Stanley: CEO of AJNA BioSciences
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Jan 2, 2026 ·47m
Dec 21, 2025 ·46m